Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and therapeutic options

Transfusion and Apheresis Science

Volumn 32, Issue 1, 2005, Pages 85-97

  Herishanu, Yair ^a   Polliack, Aaron ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Biology; Chronic lymphocytic leukemia; Pathogenesis; Prognostic factors; Treatment options

Indexed keywords

ALEMTUZUMAB; CD5 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DNA VACCINE; FLUDARABINE; MITOXANTRONE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; RITUXIMAB;

APOPTOSIS; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MICROENVIRONMENT; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; STEM CELL TRANSPLANTATION; STROMA CELL;

EID: 14344264726     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2004.10.012     Document Type: Conference Paper

References (122)

1. F. Caligaris-Cappio, and T.J. Hamblin B-cell chronic lymphocytic leukemia: a bird of a different feather J Clin Oncol 17 1 1999 399 408
2. M.S. Linet Chronic lymphocytic leukemia A. Polliack D. Catovsky The epidemiology of chronic lymphocytic leukemia 1988 Harwood Academic Publishers Chur 11 32
3. M. Sgambati, M.S. Linet, and S. Devesa Chronic lymphoid leukemias B.D. Cheson Chronic lymphoid leukemias 2nd ed 2003 M. Dekker New York 33 62
4. L.R. Goldin, R.M. Pfeiffer, X. Li, and K. Hemminki Familial Risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: Results from the Swedish family-cancer database Blood 2004
5. A.C. Rawstron, M.R. Yuille, and J. Fuller Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion Blood 100 7 2002 2289 2290
6. S. Capalbo, V. Callea, and C. Musolino Familial B-cell chronic lymphocytic leukemia in a population of patients from Southern Italy Int J Hematol 79 4 2004 354 357
7. M.R. Yuille, E. Matutes, A. Marossy, B. Hilditch, D. Catovsky, and R.S. Houlston Familial chronic lymphocytic leukaemia: a survey and review of published studies Br J Haematol 109 4 2000 794 799
8. A.C. Rawstron, M.J. Green, and A. Kuzmicki Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts Blood 100 2 2002 635 639
9. P. Ghia, G. Prato, and C. Scielzo Monoclonal CD5+ and CD5-B-lymphocyte expansions are frequent in the peripheral blood of the elderly Blood 103 6 2004 2337 2342
10. S. O'Connor, A. RAwstron, M. Plummer, P. Hillmen, R. Owen, and A. Jack Demonstration of the genotypic relationship between CLUS and clinical B-CLL Leuk Lymphoma 44 Suppl 2 2003 S13
11. M.H. Greene, R.N. Hoover, and J.F. Fraumeni Jr. Subsequent cancer in patients with chronic lymphocytic leukemia-a possible immunologic mechanism J Natl Cancer Inst 61 2 1978 337 340
12. L.B. Travis, R.E. Curtis, B.F. Hankey, and J.F. Fraumeni Jr. Second cancers in patients with chronic lymphocytic leukemia J Natl Cancer Inst 84 18 1992 1422 1427
13. M. Hisada, R.J. Biggar, M.H. Greene, J.F. Fraumeni Jr., and L.B. Travis Solid tumors after chronic lymphocytic leukemia Blood 98 6 2001 1979 1981
14. F. Fais, F. Ghiotto, and S. Hashimoto Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors J Clin Invest 102 8 1998 1515 1525
15. R.N. Damle, T. Wasil, and F. Fais Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 6 1999 1840 1847
16. T.J. Hamblin, Z. Davis, A. Gardiner, D.G. Oscier, and F.K. Stevenson Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 94 6 1999 1848 1854
17. M. Schena, L.G. Larsson, and D. Gottardi Growth- and differentiation- associated expression of bcl-2 in B-chronic lymphocytic leukemia cells Blood 79 11 1992 2981 2989
18. U. Klein, Y. Tu, and G.A. Stolovitzky Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells J Exp Med 194 11 2001 1625 1638
19. R.N. Damle, F. Ghiotto, and A. Valetto B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes Blood 99 11 2002 4087 4093
20. K. Lin, P.D. Sherrington, M. Dennis, Z. Matrai, J.C. Cawley, and A.R. Pettitt Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia Blood 100 4 2002 1404 1409
21. A. Krober, T. Seiler, and A. Benner V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood 100 4 2002 1410 1416
22. A. Rosenwald, A.A. Alizadeh, and G. Widhopf Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia J Exp Med 194 11 2001 1639 1647
23. G. Tobin, U. Thunberg, and A. Johnson Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia Blood 99 6 2002 2262 2264
24. J. Durig, H. Nuckel, and M. Cremer ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia Leukemia 17 12 2003 2426 2434
25. M. Crespo, F. Bosch, and N. Villamor ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia N Engl J Med 348 18 2003 1764 1775
26. J.A. Orchard, R.E. Ibbotson, and Z. Davis ZAP-70 expression and prognosis in chronic lymphocytic leukaemia Lancet 363 9403 2004 105 111
27. A. Wiestner, A. Rosenwald, and T.S. Barry ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile Blood 101 12 2003 4944 4951
28. M. Corcoran, J. Orchard, Z. Davis, and D. Oscier ZAP-70 methylation correlates with ZAP-70 protien expression and with IgVH gene mutational status in chronic lymphocytic leukemia Leuk Lymphoma 44 Suppl 2 2003 S15
29. Y. Vasconcelos, P. Oppezzo, F. Vullier, M. Yamamoto, G. Dighiero, and F. Davi Evaluting new surrogate markers for IgVH genes in CLL Leuk Lymphoma 44 Suppl 2 2003 S29
30. C. Hivroz, B. Geny, J.C. Brouet, and C. Grillot-Courvalin Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C J Immunol 144 6 1990 2351 2358
31. F. Michel, H. Merle-Beral, E. Legac, A. Michel, P. Debre, and G. Bismuth Defective calcium response in B-chronic lymphocytic leukemia cells. Alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx J Immunol 150 8 Pt 1 1993 3624 3633
32. A.C. Lankester, G.M. van Schijndel, C.E. van der Schoot, M.H. van Oers, C.J. van Noesel, and R.A. van Lier Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells Blood 86 3 1995 1090 1097
33. L. Chen, G. Widhopf, and L. Huynh Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia Blood 100 13 2002 4609 4614
34. S. Zupo, L. Isnardi, and M. Megna CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis Blood 88 4 1996 1365 1374
35. S. Zupo, R. Massara, and M. Dono Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD Blood 95 4 2000 1199 1206
36. S. Lanham, T. Hamblin, D. Oscier, R. Ibbotson, F. Stevenson, and G. Packham Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia Blood 101 3 2003 1087 1093
37. R.J. Collins, L.A. Verschuer, B.V. Harmon, R.L. Prentice, J.H. Pope, and J.F. Kerr Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro Br J Haematol 71 3 1989 343 350
38. P. Panayiotidis, D. Jones, K. Ganeshaguru, L. Foroni, and A.V. Hoffbrand Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro Br J Haematol 92 1 1996 97 103
39. L. Lagneaux, A. Delforge, D. Bron, C. De Bruyn, and P. Stryckmans Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells Blood 91 7 1998 2387 2396
40. P. Ghia, and F. Caligaris-Cappio The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms Adv Cancer Res 79 2000 157 173
41. P. Ghia, L. Granziero, M. Chilosi, and F. Caligaris-Cappio Chronic B cell malignancies and bone marrow microenvironment Semin Cancer Biol 12 2 2002 149 155
42. F. Caligaris-Cappio Role of the microenvironment in chronic lymphocytic leukaemia Br J Haematol 123 3 2003 380 388
43. M. Dancescu, M. Rubio-Trujillo, G. Biron, D. Bron, G. Delespesse, and M. Sarfati Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression J Exp Med 176 5 1992 1319 1326
44. M. Buschle, D. Campana, S.R. Carding, C. Richard, A.V. Hoffbrand, and M.K. Brenner Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia J Exp Med 177 1 1993 213 218
45. F.T. Cordingley, A. Bianchi, and A.V. Hoffbrand Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies Lancet 1 8592 1988 969 971
46. H.E. Heslop, A.C. Bianchi, and F.T. Cordingley Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders J Exp Med 172 6 1990 1729 1734
47. C. van Kooten, I. Rensink, L. Aarden, and R. van Oers Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells Blood 80 5 1992 1299 1306
48. A. Olsson, T. Diaz, and M. Aguilar-Santelises Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D Leukemia 15 12 2001 1868 1877
49. M. MacFarlane, N. Harper, and R.T. Snowden Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia Oncogene 21 44 2002 6809 6818
50. P. Panayiotidis, K. Ganeshaguru, L. Foroni, and A.V. Hoffbrand Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia Leukemia 9 7 1995 1227 1232
51. D. Wang, G.J. Freeman, H. Levine, J. Ritz, and M.J. Robertson Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies Br J Haematol 97 2 1997 409 417
52. J.F. Williams, M.J. Petrus, and J.A. Wright Fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous fasL-expressing T cells Br J Haematol 107 1 1999 99 105
53. G. Roue, L. Lancry, F. Duquesne, V. Salaun, X. Troussard, and B. Sola Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia Leuk Res 25 11 2001 967 980
54. P. Chu, D. Deforce, and I.M. Pedersen Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia Proc Natl Acad Sci USA 99 6 2002 3854 3859
55. T. Mainou-Fowler, J.A. Copplestone, and A.G. Prentice Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells J Clin Pathol 48 5 1995 482 487
56. P. Panayiotidis, K. Ganeshaguru, S.A. Jabbar, and A.V. Hoffbrand Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro Br J Haematol 85 3 1993 439 445
57. N.E. Kay, L. Han, N. Bone, and G. Williams Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis Br J Haematol 112 3 2001 760 767
58. P. Francia di Celle, S. Mariani, L. Riera, A. Stacchini, G. Reato, and R. Foa Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion Blood 87 10 1996 4382 4389
59. R. Rojas, J. Roman, and A. Torres Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage Leukemia 10 11 1996 1782 1788
60. S. Molica, G. Vitelli, D. Levato, G.M. Gandolfo, and V. Liso Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia Br J Haematol 107 3 1999 605 610
61. P. Ghia, G. Strola, and L. Granziero Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 Eur J Immunol 32 5 2002 1403 1413
62. L. Granziero, P. Ghia, and P. Circosta Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia Blood 97 9 2001 2777 2783
63. J.A. Burger, M. Burger, and T.J. Kipps Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells Blood 94 11 1999 3658 3667
64. R. Mohle, C. Failenschmid, F. Bautz, and L. Kanz Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1) Leukemia 13 12 1999 1954 1959
65. J.A. Burger, N. Tsukada, M. Burger, N.J. Zvaifler, M. Dell'Aquila, and T.J. Kipps Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1 Blood 96 8 2000 2655 2663
66. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989;110(3):236-8
67. B.D. Cheson, J.M. Bennett, and K.R. Rai Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group Am J Hematol 29 3 1988 152 163
68. D. Oscier, C. Fegan, and P. Hillmen Guidelines on the diagnosis and management of chronic lymphocytic leukaemia Br J Haematol 125 3 2004 294 317
69. E. Matutes, K. Owusu-Ankomah, and R. Morilla The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL Leukemia 8 10 1994 1640 1645
70. E.J. Moreau, E. Matutes, and R.P. A'Hern Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b) Am J Clin Pathol 108 4 1997 378 382
71. J.M. Bennett, D. Catovsky, and M.T. Daniel Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group J Clin Pathol 42 6 1989 567 584
72. T.H. Que, J.G. Marco, and J. Ellis Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology Blood 82 2 1993 571 575
73. S.M. Escudier, J.M. Pereira-Leahy, and J.W. Drach Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia Blood 81 10 1993 2702 2707
74. R. Gascoyne Differential diagnosis of the chronic B-cell lymphoid leukemias B.D. Cheson Chronic Lymphoid Leukemias 2nd ed. 2001 Marcel Dekker New York 209 230
75. K.R. Rai, A. Sawitsky, E.P. Cronkite, A.D. Chanana, R.N. Levy, and B.S. Pasternack Clinical staging of chronic lymphocytic leukemia Blood 46 2 1975 219 234
76. J.L. Binet, A. Auquier, and G. Dighiero A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 48 1 1981 198 206
77. S. Molica Progression and survival studies in early chronic lymphocytic leukemia Blood 78 4 1991 895 899
78. M. Dhodapkar, A. Tefferi, J. Su, and R.L. Phyliky Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study Leukemia 7 8 1993 1232 1235
79. F.R. Mauro, R. Foa, and D. Giannarelli Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases Blood 94 2 1999 448 454
80. T.D. Shanafelt, S.M. Geyer, and N.E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood 103 4 2004 1202 1210
81. A. Polliack Current therapeutic options for subgroups of chronic lymphocytic leukemia. Planning risk-adapted treatment according to recognized prognostic factors Haematologica 88 7 2003 726 729
82. E. Montserrat, N. Vinolas, J.C. Reverter, and C. Rozman Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages Nouv Rev Fr Hematol 30 5-6 1988 359 361
83. Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol 1990;76(1):45-57
84. E. Montserrat, J. Sanchez-Bisono, N. Vinolas, and C. Rozman Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance Br J Haematol 62 3 1986 567 575
85. C. Rozman, E. Montserrat, and J.M. Rodriguez-Fernandez Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases Blood 64 3 1984 642 648
86. E. Montserrat, and C. Rozman Chronic lymphocytic leukemia: present status Ann Oncol 6 3 1995 219 235
87. M. Sarfati, S. Chevret, and C. Chastang Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia Blood 88 11 1996 4259 4264
88. M. Hallek, I. Langenmayer, and C. Nerl Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia Blood 93 5 1999 1732 1737
89. H. Dohner, S. Stilgenbauer, and A. Benner Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 26 2000 1910 1916
90. D.G. Oscier, A.C. Gardiner, and S.J. Mould Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors Blood 100 4 2002 1177 1184
91. M.L. Keating, and S.H.M. Kantarjian The serum beta-2-microglobulin level is more powerful than stage in predicting response and survival in CLL Blood 86 1995 606a
92. T.J. Hamblin, J.A. Orchard, and R.E. Ibbotson CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease Blood 99 3 2002 1023 1029
93. G. Juliusson, D.G. Oscier, and M. Fitchett Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities N Engl J Med 323 11 1990 720 724
94. H. Dohner, S. Stilgenbauer, and M.R. James 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis Blood 89 7 1997 2516 2522
95. S. el Rouby, A. Thomas, and D. Costin p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression Blood 82 11 1993 3452 3459
96. H. Dohner, K. Fischer, and M. Bentz p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood 85 6 1995 1580 1589
97. Proceedings of the meeting on chronic lymphocytic leukemia: Is it a curable disease? Haematologica 2002;87(Suppl 10):1-79
98. M. Hallek Risk- and age-adapted management of CLL: current and future clinical trials of the German CLL study group Hematologica 87 Suppl 11 2002 37 38
99. M. Brugiatelli, M. Domenico, M. Donato, and S. Neri B-cell chronic lymphocytic leukemia: different therapies for different diseases? Hematologica 87 Suppl 11 2002 34 36
100. T. Vallespi, E. Montserrat, and M.A. Sanz Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients Br J Haematol 77 4 1991 478 485
101. J.C. Byrd, T. Murphy, and R.S. Howard Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity J Clin Oncol 19 8 2001 2153 2164
102. H. Schulz, S.K. Klein, and U. Rehwald Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia Blood 100 9 2002 3115 3120
103. J.C. Byrd, B.L. Peterson, and V.A. Morrison Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood 101 1 2003 6 14
104. S. O'Brien Mabthera in chronic lymphocytic leukemia Hematologica 87 Suppl 11 2002 50 53
105. M. Keating, T. Manshouri, and S. O'Brien A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia (CLL) Blood 100 11 2002 205a
106. K. Rai, J. Byrd, B. Peterson, and R. Larson A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901 Blood 100 11 2002 205a
107. P. Hillmen MabCampath in chronic lymphocytic leukemia Hematologica 87 Suppl 11 2002 47 49
108. D. Provan, L. Bartlett-Pandite, and C. Zwicky Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation Blood 88 6 1996 2228 2235
109. E. Cabezudo, E. Matutes, M. Ramrattan, R. Morilla, and D. Catovsky Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry Leukemia 11 11 1997 1909 1914
110. A.C. Rawstron, B. Kennedy, and P.A. Evans Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy Blood 98 1 2001 29 35
111. K. Rai, S. O'Brien, and C. Cunningham Genasense (Bcl-2 Antisense) Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Phase 1 and 2 Results Blood 100 11 2002 384a
112. B. Cheson New drugs: can they cure CLL? Hematologica 87 Suppl 11 2002 56 58
113. J. Esteve, N. Villamor, and D. Colomer Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status Leukemia 15 3 2001 445 451
114. I.F. Khouri, R.M. Saliba, and S.A. Giralt Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Blood 98 13 2001 3595 3599
115. I.F. Khouri, M.J. Keating, R.M. Saliba, and R.E. Champlin Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation Cytotherapy 4 3 2002 217 221
116. I. Khouri Reduced intensity regimens for CLL: The MD Anderson experience Hematologica 87 Suppl 11 2002 76 77
117. G. Bandini, F. Bonifazi, and S. Falcioni Allogeneic hematopoietic stem cell transplantation for CLL: Background and results from the EBMT Registry Hematologica 87 11 2002 68 75
118. M. Michallet, A. Thiebaut, and P. Dreger Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP) Br J Haematol 108 3 2000 595 601
119. D.W. Milligan, S. Fernandes, and R. Dasgupta Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses Blood 105 1 2005 397 404
120. P. Dreger, R. Brand, and J. Hansz Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning Leukemia 17 5 2003 841 848
121. J. Schetelig, C. Thiede, and M. Bornhauser Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group J Clin Oncol 21 14 2003 2747 2753
122. C. Rozman, and E. Montserrat Chronic lymphocytic leukemia N Engl J Med 333 16 1995 1052 1057